Obsidio Embolic Closes Target Vessels in Registry
Final results from the OCCLUDE registry were published in the Journal of Vascular and Interventional Radiology and announced by Boston Scientific on Tuesday, November 17, 2026. The prospective, real-world registry covered 125 patients treated with the Obsidio conformable embolic at 19 United States hospitals. Target vessel occlusion reached 100 percent, no target vessel rebleeding was reported through 30 days, and freedom from adverse events was 97.4 percent at 30 days.
Edited and fact-checked by Stephen Sprague
OCCLUDE is a registry, so it shows the device working in routine practice rather than beating a rival in a trial. Hospitals reading it get a 30-day performance record from 125 real cases, and the comparison and longer follow-up questions stay open.
A catheter reached its target vessel in 125 patients across 19 hospitals, and the vessel closed every time.
Boston Scientific announced the publication on Tuesday, November 17, 2026. The final OCCLUDE results appeared in the Journal of Vascular and Interventional Radiology, in a paper by Ketan Y. Shah, MD, and co-authors. OCCLUDE was a prospective, multicenter, real-world registry, not a randomized trial. It had no control arm, so its numbers describe what happened in treated patients rather than a comparison against another device or technique.
Doctors used the Obsidio conformable embolic for diverse embolization indications in 19 target vessels. Patients ranged in age from 18 to 92 years. Embolization works by blocking a vessel on purpose, and doctors use it to stop bleeding or to cut blood flow to tissue that shouldn't have it. For a patient bleeding after trauma or surgery, a closed vessel can mean no open operation that night.
Target vessel occlusion reached 100 percent of cases in the registry. No patient had rebleeding in a target vessel through 30 days of follow-up. A closed vessel that reopens is the failure mode doctors watch for first, because the bleeding the procedure stopped can start again. Thirty days is the window this registry reports, and it doesn't speak to what happens in month two or month six.
Freedom from adverse events stood at 97.4 percent through 30 days. The figure is a registry-wide rate across all 125 patients and all 19 hospitals. It isn't a guarantee for any single patient, whose risk depends on the vessel treated, the indication and the rest of their condition. The publication reports the rate as a group outcome, and readers should keep it at that level.
Adjunctive embolics joined the Obsidio device in 23.6 percent of procedures. Doctors added beads, coils or gelatin sponges in those cases, so the 100 percent occlusion figure belongs to the procedure as performed, not to the Obsidio material alone in every case. That distinction matters for any hospital weighing the device against its current shelf stock.
One boundary belongs on the record. Boston Scientific makes the Obsidio embolic, and the company announced the publication, so the announcement itself is a manufacturer's statement. The results it points to appeared in a peer-reviewed journal, the Journal of Vascular and Interventional Radiology, under named clinical authors. Readers can weigh both facts at once, and the registry's design limits, stated above, don't change either way.
Registries like OCCLUDE earn their place by showing how a device performs outside a tightly selected trial population. The 125 patients here came from routine practice at 19 hospitals, with the age spread and mixed indications that real practice carries. The next evidence step is comparative and longer, and this publication doesn't claim to be either one.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.